|
Orthologous residues
|
|
hnRNP I (human): S16‑p, hnRNP I (mouse): S16‑p, hnRNP I iso2 (mouse): S16‑p, hnRNP I (rat): S16‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphoamino acid analysis, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], oocyte [CPEB (mouse)], PC-12 (chromaffin)
|
|
Cellular systems studied:
cell lines, primary cells
|
|
Species studied:
frog, human, mouse, rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (human)
|
genetic transfer of constitutively active upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
cAMP analog
|
|
|
|
increase
|
|
|
forskolin
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
